AMLN Amylin Pharmaceuticals, Inc. (MM)

Bradbury Also Appointed to the Board of Directors SAN DIEGO, June 7 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. (NASDAQ:AMLN) today announced that Daniel M. Bradbury has been promoted to President and Chief Operating Officer. Bradbury was also appointed to Amylin's Board of Directors and as part of the company's succession plan, will become Chief Executive Officer within a year. "Amylin has evolved from a research and development organization to a commercial enterprise with two first-in-class medicines for diabetes. The acceptance of BYETTA(R) and SYMLIN(R) as meaningful and important new therapies has set Amylin on a trajectory for long-term growth," said Ginger L. Graham, Chief Executive Officer of Amylin Pharmaceuticals. "Dan's promotion and our succession plan reflect the commitment of the management team and the Board to ensure effective leadership for the long term. We will continue to work together to build a sustainable growth company, leading with innovative science that has real impact for people." Joseph C. Cook, Jr., Chairman of the Board commented, "Under Ginger's leadership, Amylin has emerged as a top 10 biopharmaceutical company with significant growth opportunities ahead. Dan has been a key player in Amylin's development and a part of the leadership team for the past twelve years. He has a broad knowledge of the biopharmaceutical industry and is committed to putting patients first. This promotion and succession plan ensures an orderly and effective transition to prepare Amylin for the next phase of growth." "We have a great team of employees committed to our mission to bring innovative medicines to patients who need them and a growing pipeline for the future," said Daniel M. Bradbury, President and Chief Operating Officer of Amylin Pharmaceuticals. "I am excited about the future and look forward to the opportunity to join the Amylin Board and take on increasing leadership responsibilities." Mr. Bradbury, 45, has served as Chief Operating Officer since June 2003. He previously served as Executive Vice President from June 2000 until his promotion in June 2003. He joined Amylin in 1994 and has held officer-level positions in Corporate Development and Marketing during that time. Prior to joining Amylin, Mr. Bradbury spent ten years at SmithKline Beecham Pharmaceuticals, where he held a number of sales and marketing positions. He is a member of the board of directors of Cerexa, Inc., Illumina, Inc. and Novacea, Inc. He also serves as a board member for BIOCOM. Mr. Bradbury is a member of the Royal Pharmaceutical Society of Great Britain and serves as Chair of the Advisory Council of the Keck Graduate Institute. He received a Bachelor of Pharmacy from Nottingham University and a Diploma in Management Studies from Harrow and Ealing Colleges of Higher Education. About Amylin Pharmaceuticals Amylin Pharmaceuticals is a biopharmaceutical company committed to improving lives through the discovery, development and commercialization of innovative medicines. Amylin has developed and gained approval for two first-in-class medicines for diabetes, SYMLIN(R) (pramlintide acetate) injection and BYETTA(R) (exenatide) injection. Amylin's research and development activities leverage the company's expertise in metabolism to develop promising therapies to treat diabetes, obesity and cardiovascular disease. Amylin is located in San Diego, California with over 1200 employees nationwide. Further information on Amylin Pharmaceuticals is available at http://www.amylin.com/. Safe Harbor/Forward Looking Statements This press release contains forward-looking statements about Amylin. The company's actual results could differ materially from those discussed in this press release due to a number of risks and uncertainties, including those described in the company's recently filed Form 10-Q. Amylin disclaims any obligation to update these forward-looking statements. DATASOURCE: Amylin Pharmaceuticals, Inc. CONTACT: Alice Bahner, Executive Director, Investor Relations of Amylin Pharmaceuticals, Inc., +1-858-552-2200 Web site: http://www.amylin.com/

Copyright